Kenacort-A 10

Triamcinolone Acetonide, the active ingredient in Kenacort-A 10, is a corticosteroid presented as a sterile injectable preparation for intraarticular, intrabursal, and intradermal use. It reduces inflammation in joints, bursae and skin lesions. GNH USA supplies Kenacort-A 10 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kenacort-A 10 is a corticosteroid used for inflammatory conditions affecting joints, bursae and skin. - Osteoarthritis: alleviates joint pain and swelling by reducing local inflammation. - Rheumatoid arthritis: diminishes synovial inflammation and improves joint function. - Bursitis: decreases bursal swelling and discomfort. - Tendinitis: reduces tendon sheath inflammation and pain. - Psoriasis (intralesional): improves plaque lesions by suppressing local immune response.

Adverse reactions may vary with the route of administration and patient factors.

Common Side Effects: - Pain or tenderness at the injection site - Bruising or discoloration - Transient hyperglycemia - Mild skin thinning or atrophy - Flushing or facial warmth - Headache

Serious or Rare Side Effects: - Infection at the injection site - Tendon rupture or weakening - Adrenal suppression - Severe hyperglycemia or diabetic ketoacidosis - Anaphylactic or severe allergic reaction - Osteonecrosis of the jaw or bone tissue

Before using Kenacort-A 10, consider the following safety measures. - Infection risk: assess for active infections before injection. - Blood glucose monitoring: patients with diabetes may experience elevated glucose levels. - Osteoporosis: use caution in patients with reduced bone density. - Systemic corticosteroid effects: avoid concurrent high‑dose systemic steroids when possible. - Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Triamcinolone acetonide may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic steroid exposure. - Live vaccines: risk of reduced vaccine efficacy and infection. - Systemic immunosuppressants: additive immunosuppression increasing infection risk.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of gastrointestinal ulceration or bleeding. - Antidiabetic agents: may require dose adjustment due to hyperglycemia. - Diuretics: potential for hypokalemia. - Anticoagulants: increased bleeding tendency at injection sites.